Mirae Asset Global Investments Co. Ltd. Sells 89,057 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mirae Asset Global Investments Co. Ltd. lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 76.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,288 shares of the medical research company’s stock after selling 89,057 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in IQVIA were worth $5,416,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. E. Ohman J or Asset Management AB grew its position in shares of IQVIA by 12.1% during the fourth quarter. E. Ohman J or Asset Management AB now owns 8,361 shares of the medical research company’s stock valued at $1,643,000 after purchasing an additional 900 shares in the last quarter. GDS Wealth Management boosted its stake in IQVIA by 8.4% during the fourth quarter. GDS Wealth Management now owns 59,529 shares of the medical research company’s stock valued at $11,698,000 after buying an additional 4,636 shares during the last quarter. Oregon Pacific Wealth Management LLC purchased a new position in IQVIA during the 4th quarter valued at approximately $470,000. Magnolia Capital Advisors LLC raised its stake in IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 74 shares in the last quarter. Finally, Western Pacific Wealth Management LP increased its holdings in shares of IQVIA by 44.4% in the 4th quarter. Western Pacific Wealth Management LP now owns 845 shares of the medical research company’s stock worth $166,000 after buying an additional 260 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV opened at $208.13 on Friday. The firm has a market capitalization of $37.78 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The business’s 50-day moving average is $200.53 and its two-hundred day moving average is $219.80. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IQV. Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.